Watch the MOA video to find out how MacroBID® does not contribute towards
rising antibiotic resistance in lower urinary tract infections

Click here for MOA video PI & references

MacroBID® 100 mg prolonged-release capsules
is licensed to be taken twice daily for 7 days for acute
or recurrent uncomplicated UTI and pyelitis5

*Nitrofurantoin is contraindicated in patients with renal dysfunction and in patients with an eGFR of less than 45 ml/min. Nitrofurantoin may be used with caution as short-course therapy only for the treatment of uncomplicated lower UTI in individual cases with an eGFR between 30-44 ml/min to treat resistant pathogens, when the benefits are expected to outweigh the risks.5 GFR stages classified as: mild (60-89 ml/min/1.73m2); mild-moderate (45-59 ml/min/1.73m2); moderate-severe (30-44 ml/min/1.73m2); severe (15-29 ml/min/1.73m2) and kidney failure (<15 ml/min/1.73m2).10

Nitrofurantoin is contraindicated in infants under 3 months of age as well as pregnant patients at term (during labour and delivery) because of the theoretical possibility of haemolytic anaemia in the foetus or in the newborn infant due to immature erythrocyte enzyme systems.5

Resist the resistance with MacroBID® – your tool in the fight against resistance in lower UTIs

Email icon

To arrange a call with the MacroBID team contact:
Visit for more information

Prescribing information and references

Date of preparation: November 2021 ADV/MAB/PM/0315